{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,6]],"date-time":"2026-09-06T05:07:54Z","timestamp":1788671274687,"version":"build-2803163510"},"reference-count":41,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T00:00:00Z","timestamp":1695254400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Iuliu Hatieganu University\u2014School of Doctoral Studies","award":["PN-III-P4-ID-PCE-2020-1118"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2020-1118"]}]},{"name":"Iuliu Hatieganu University\u2014School of Doctoral Studies","award":["PCE 225\/2021"],"award-info":[{"award-number":["PCE 225\/2021"]}]},{"name":"Iuliu Hatieganu University\u2014School of Medicine","award":["PN-III-P4-ID-PCE-2020-1118"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2020-1118"]}]},{"name":"Iuliu Hatieganu University\u2014School of Medicine","award":["PCE 225\/2021"],"award-info":[{"award-number":["PCE 225\/2021"]}]},{"name":"Romanian National Ministry of Research, Innovation and Digitalization","award":["PN-III-P4-ID-PCE-2020-1118"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2020-1118"]}]},{"name":"Romanian National Ministry of Research, Innovation and Digitalization","award":["PCE 225\/2021"],"award-info":[{"award-number":["PCE 225\/2021"]}]},{"name":"European Economic Space between Romania and Iceland 2021\u20132023","award":["PN-III-P4-ID-PCE-2020-1118"],"award-info":[{"award-number":["PN-III-P4-ID-PCE-2020-1118"]}]},{"name":"European Economic Space between Romania and Iceland 2021\u20132023","award":["PCE 225\/2021"],"award-info":[{"award-number":["PCE 225\/2021"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Objective: Our primary objective was to describe the baseline characteristics, main reasons for intensive care unit (ICU) admission, and interventions required in the ICU across patients who received CAR-T cell immunotherapy. The secondary objectives were to evaluate different outcomes (ICU mortality) across patients admitted to the ICU after having received CAR-T cell therapy. Materials and Methods. We performed a medical literature review, which included MEDLINE, Embase, and Cochrane Library, of studies published from the inception of the databases until 2022. We conducted a systematic review with meta-analyses of proportions of several studies, including CAR-T cell-treated patients who required ICU admission. Outcomes in the meta-analysis were evaluated using the random-effects model. Results: We included four studies and analyzed several outcomes, including baseline characteristics and ICU-related findings. CAR-T cell recipients admitted to the ICU are predominantly males (62% CI-95% (57\u201366)). Of the total CAR-T cell recipients, 4% CI-95% (3\u20135) die in the hospital, and 6% CI-95% (4\u20139) of those admitted to the ICU subsequently die. One of the main reasons for ICU admission is acute kidney injury (AKI) in 15% CI-95% (10\u201319) of cases and acute respiratory failure in 10% CI-95% (6\u201313) of cases. Regarding the interventions initiated in the ICU, 18% CI-95% (13\u201322) of the CAR-T recipients required invasive mechanical ventilation during their ICU stay, 23% CI-95% (16\u201330) required infusion of vasoactive drugs, and 1% CI-95% (0.1\u20133) required renal replacement therapy (RRT). 18% CI-95% (13\u201322) of the initially discharged patients were readmitted to the ICU within 30 days, and the mean length of hospital stay is 22 days CI-95% (19\u201325). The results paint a current state of matter in CAR-T cell recipients admitted to the ICU. Conclusions: To better understand immunotherapy-related complications from an ICU standpoint, acknowledge the deteriorating patient on the ward, reduce the ICU admission rate, advance ICU care, and improve the outcomes of these patients, a standard of care and research regarding CAR-T cell-based immunotherapies should be created. Studies that are looking from the perspective of intensive care are highly warranted because the available literature regarding this area is scarce.<\/jats:p>","DOI":"10.3390\/jcm12186098","type":"journal-article","created":{"date-parts":[[2023,9,21]],"date-time":"2023-09-21T21:16:49Z","timestamp":1695331009000},"page":"6098","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Outcomes of CAR-T Cell Therapy Recipients Admitted to the ICU: In Search for a Standard of Care\u2014A Brief Overview and Meta-Analysis of Proportions"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8292-911X","authenticated-orcid":false,"given":"Catalin","family":"Constantinescu","sequence":"first","affiliation":[{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"},{"name":"Department of Anesthesia and Intensive Care, Iuliu Hatieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"},{"name":"Intensive Care Unit, Emergency Hospital, 400006 Cluj-Napoca, Romania"},{"name":"Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Moisoiu","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Iuliu Hatieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9397-0791","authenticated-orcid":false,"given":"Bogdan","family":"Tigu","sequence":"additional","affiliation":[{"name":"Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6252-6281","authenticated-orcid":false,"given":"David","family":"Kegyes","sequence":"additional","affiliation":[{"name":"Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5500-1519","authenticated-orcid":false,"given":"Ciprian","family":"Tomuleasa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, 400349 Cluj-Napoca, Romania"},{"name":"Medfuture Research Center for Advanced Medicine, Iuliu Hatieganu University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,21]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13045-017-0423-1","article-title":"New development in CAR-T cell therapy","volume":"10","author":"Wang","year":"2017","journal-title":"J. Hematol. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zhu, L., Zhang, H., Chen, S., and Xiao, Y. (2022). CAR-T Cell Therapy in Hematological Malignancies: Current Opportunities and Challenges. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.927153"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1038\/s41409-019-0602-5","article-title":"Insight into mechanisms associated with cytokine release syndrome and neurotoxicity after CD19 CAR-T cell immunotherapy","volume":"54","author":"Chou","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.hemonc.2019.05.005","article-title":"Cytokine release syndrome and neurologic toxicities associated with chimeric antigen receptor T-Cell therapy: A comprehensive review of emerging grading models","volume":"13","author":"Chavez","year":"2020","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1164\/rccm.202002-0286LE","article-title":"ICU Resource Use in Critically Ill Patients Following Chimeric Antigen Receptor T-Cell Therapy","volume":"202","author":"Brown","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): An international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.hemonc.2020.09.004","article-title":"C-reactive protein and ferritin levels and length of intensive care unit stay in patients with B-cell lymphomas treated with axicabtagene ciloleucel","volume":"14","author":"Melody","year":"2021","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_12","unstructured":"(2022, September 04). Cochrane Handbook for Systematic Reviews of Interventions. Available online: https:\/\/training.cochrane.org\/handbook."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13613-022-01036-2","article-title":"The use of ICU resources in CAR-T cell recipients: A hospital-wide study","volume":"12","author":"Valade","year":"2022","journal-title":"Ann. Intensive Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control. Clin. Trials"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1002\/sim.1186","article-title":"Quantifying heterogeneity in a meta-analysis","volume":"21","author":"Higgins","year":"2002","journal-title":"Stat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Burns, E.A., Gentille, C., Trachtenberg, B., Pingali, S.R., and Anand, K. (2021). Cardiotoxicity Associated with Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Recognition, Risk Factors, and Management. Diseases, 9.","DOI":"10.3390\/diseases9010020"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1007\/s00134-014-3373-x","article-title":"Trends in admission prevalence, illness severity and survival of haematological patients treated in Dutch intensive care units","volume":"40","author":"Verburg","year":"2014","journal-title":"Intensive Care Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"R137","DOI":"10.1186\/cc8016","article-title":"Admission factors associated with hospital mortality in patients with haematological malignancy admitted to UK adult, general critical care units: A secondary analysis of the ICNARC Case Mix Programme Database","volume":"13","author":"Hampshire","year":"2009","journal-title":"Crit. Care"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.3109\/10428194.2012.753446","article-title":"Delayed intensive care unit admission is associated with increased mortality in patients with cancer with acute respiratory failure","volume":"54","author":"Mokart","year":"2013","journal-title":"Leuk. Lymphoma"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e120","DOI":"10.1097\/CCM.0000000000003526","article-title":"Long-Term Outcome of Patients with a Hematologic Malignancy and Multiple Organ Failure Admitted at the Intensive Care","volume":"47","author":"Arbous","year":"2019","journal-title":"Crit. Care Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e6947","DOI":"10.7717\/peerj.6947","article-title":"Comparison of the National Early Warning Score (NEWS) and the Modified Early Warning Score (MEWS) for predicting admission and in-hospital mortality in elderly patients in the pre-hospital setting and in the emergency department","volume":"7","author":"Mitsunaga","year":"2019","journal-title":"PeerJ"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Constantinescu, C., Bodolea, C., Pasca, S., Teodorescu, P., Dima, D., Rus, I., Tat, T., Achimas-Cadariu, P., Tanase, A., and Tomuleasa, C. (2019). Clinical Approach to the Patient in Critical State Following Immunotherapy and\/or Stem Cell Transplantation: Guideline for the On-Call Physician. J. Clin. Med., 8.","DOI":"10.3390\/jcm8060884"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Constantinescu, C., Pasca, S., Iluta, S., Gafencu, G., Santa, M., Jitaru, C., Teodorescu, P., Dima, D., Zdrenghea, M., and Tomuleasa, C. (2021). The Predictive Role of Modified Early Warning Score in 174 Hematological Patients at the Point of Transfer to the Intensive Care Unit. J. Clin. Med., 10.","DOI":"10.3390\/jcm10204766"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1007\/s00134-021-06506-y","article-title":"Surviving sepsis campaign: International guidelines for management of sepsis and septic shock 2021","volume":"47","author":"Evans","year":"2021","journal-title":"Intensive Care Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified t-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1080\/10428194.2021.1881506","article-title":"Characteristics and risk factors of infections following CD28-based CD19 CAR-T cells","volume":"62","author":"Sherman","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"5174","DOI":"10.1182\/bloodadvances.2020002592","article-title":"Diagnostic biomarkers to differentiate sepsis from cytokine release syndrome in critically ill children","volume":"4","author":"Diorio","year":"2020","journal-title":"Blood Adv."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"e000742","DOI":"10.1136\/jitc-2020-000742","article-title":"Continuous renal replacement therapy in cytokine release syndrome following immunotherapy or cellular therapies?","volume":"8","author":"Constantinescu","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Bottari, G., Lorenzetti, G., Severini, F., Cappoli, A., Cecchetti, C., and Guzzo, I. (2021). Role of Hemoperfusion With CytoSorb Associated with Continuous Kidney Replacement Therapy on Renal Outcome in Critically Ill Children with Septic Shock. Front. Pediatr., 9.","DOI":"10.3389\/fped.2021.718049"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.jcrc.2012.04.018","article-title":"Cross-validation of a sequential organ failure assessment score-based model to predict mortality in patients with cancer admitted to the intensive care unit","volume":"27","author":"Ensor","year":"2012","journal-title":"J. Crit. Care"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1793","DOI":"10.1097\/00003246-199811000-00016","article-title":"Use of the SOFA Score to assess the incidence of organ dysfunction\/failure in intensive care units: Results of a Multicenter, Prospective Study. Working group on \u201csepsis-related problems\u201d of the European Society of Intensive Care Medicine","volume":"26","author":"Vincent","year":"1998","journal-title":"Crit. Care Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1007\/s00134-012-2791-x","article-title":"Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: A single center study","volume":"39","author":"Oeyen","year":"2013","journal-title":"Intensive Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1378\/chest.14-1313","article-title":"BLUE-protocol and FALLS-protocol: Two applications of lung ultrasound in the critically ill","volume":"147","author":"Lichtenstein","year":"2015","journal-title":"Chest"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jcrc.2018.11.031","article-title":"Crystalloids vs. colloids for fluid resuscitation in the Intensive Care Unit: A systematic review and meta-analysis","volume":"50","author":"Martin","year":"2019","journal-title":"J. Crit. Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hon.2591","article-title":"CAR T-Cell Therapy: Full speed ahead","volume":"37","author":"Sermer","year":"2019","journal-title":"Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00134-005-2836-5","article-title":"Outcome in severely ill patients with hematological malignancies who received intravenous chemotherapy in the intensive care unit","volume":"32","author":"Benoit","year":"2006","journal-title":"Intensive Care Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/6098\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:54:51Z","timestamp":1760129691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/18\/6098"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,21]]},"references-count":41,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2023,9]]}},"alternative-id":["jcm12186098"],"URL":"https:\/\/doi.org\/10.3390\/jcm12186098","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,21]]}}}